1De Matteo RP, Lewis JJ,Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg, 2000,231 : 51-58.
2Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med,2002,347:472-480.
3Franquemont DW. Differentiation and risk assessment of gastrointestinal stromors. Am J Clin Pathol, 1995,103:41-47.
3Miettinen M,Blay JY,Sobin LH.Mesenchymal tumours of the stomach.WHO classification of tumours.Pathology and genetics of tumours of digestive system[M].Lyon:IARC Press,2000,17:62-65.
4Miettinen M,Sarlomo-Rikala M,Lassota J.Gastrointestinal stromal tumors:recent advances in understanding of their biology[J].Hum Pathol,1999,30(5):1213-1220.
5Rossi CR,Mocellin S,Mencarelli R,et al.Gastrointestinalstromal tumors:from a surgical to a molecular approach[J].Int J Cancer,2003,107(2):171-176.
6Clary BM,DeMatteo RP,Lewis JJ,et al.Gastrointestinal stromaltumors and leiomyosmcoma of the abdomen and retroperitoneum:a clinical comparison[J].Ann Surg Oncol,2001,8(25):290-299.
7Plaat BE,Hollema H,Molenaar WM,et al.Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors:differences in clinical outcome and expression of multidrug resistance proteins[J].J Clin Oncol,2000,18(18):3211-3220.
